# PAVmed Inc.: overview PAVM · Nasdaq · CIK 1624326 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pavm.md) · [Financials](/companies/pavm/financials.md) · [Filings](/companies/pavm/filings.md) · [Insiders](/companies/pavm/insiders.md) Latest reported revenue: [$33.0k](/filings/0001437749-26-027733.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-027733). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [996](/filings/0001493152-25-022017.md) | [10.0 d](/filings/0001437749-26-010115.md) | [8.0](/filings/0001437749-26-017121.md) | [6.0](/filings/0001437749-26-027733.md) | [5.0](/filings/0001493152-25-022017.md) | [52.0 d](/filings/0001437749-26-010115.md) | [22.0](/filings/0001437749-26-017121.md) | [33.0](/filings/0001437749-26-027733.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1162.4%)](/filings/0001493152-25-022017.md) | [(51870.0%) d](/filings/0001437749-26-010115.md) | [(68075.0%)](/filings/0001437749-26-017121.md) | [(78583.3%)](/filings/0001437749-26-027733.md) | [(96880.0%)](/filings/0001493152-25-022017.md) | [(13082.7%) d](/filings/0001437749-26-010115.md) | [(36522.7%)](/filings/0001437749-26-017121.md) | [(21278.8%)](/filings/0001437749-26-027733.md) | | Net margin | % | [6465.8%](/filings/0001493152-25-022017.md) | [14310.0% d](/filings/0001437749-26-010115.md) | [237100.0%](/filings/0001437749-26-017121.md) | [(198683.3%)](/filings/0001437749-26-027733.md) | [(107660.0%)](/filings/0001493152-25-022017.md) | [(2428.8%) d](/filings/0001437749-26-010115.md) | [(272.7%)](/filings/0001437749-26-017121.md) | [(16315.2%)](/filings/0001437749-26-027733.md) | | Diluted EPS | $ per share | [1.44](/filings/0001493152-25-022017.md) | not reported | [10.10](/filings/0001437749-26-017121.md) | [(22.08)](/filings/0001437749-26-027733.md) | [(0.29)](/filings/0001493152-25-022017.md) | not reported | [(4.42)](/filings/0001437749-26-017121.md) | [(0.87)](/filings/0001437749-26-027733.md) | | Free cash flow | $k | [(8,889) d](/filings/0001493152-25-022017.md) | [90.0 d](/filings/0001437749-26-010115.md) | [(1,587)](/filings/0001437749-26-017121.md) | [(1,186) d](/filings/0001437749-26-027733.md) | [(899) d](/filings/0001493152-25-022017.md) | [(1,565) d](/filings/0001437749-26-010115.md) | [(2,642)](/filings/0001437749-26-017121.md) | [(2,676) d](/filings/0001437749-26-027733.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.5](/filings/0001493152-23-007481.md) | [0.4](/filings/0001493152-24-011172.md) | [2.5](/filings/0001641172-25-000364.md) | [3.0](/filings/0001437749-26-010115.md) | [0.1](/filings/0001437749-26-010115.md) | | Gross margin | % | [(17.0%)](/filings/0001493152-22-009202.md) | not reported | not reported | not reported | not reported | | Operating margin | % | [(10878.6%)](/filings/0001493152-23-007481.md) | [(24161.0%)](/filings/0001493152-24-011172.md) | [(2805.7%)](/filings/0001641172-25-000364.md) | [(1485.4%)](/filings/0001437749-26-010115.md) | [(30712.7%)](/filings/0001437749-26-010115.md) | | Net margin | % | [(10069.4%)](/filings/0001493152-23-007481.md) | [(23602.9%)](/filings/0001493152-24-011172.md) | [(2617.3%)](/filings/0001641172-25-000364.md) | [1328.6%](/filings/0001437749-26-010115.md) | [564.8%](/filings/0001437749-26-010115.md) | | Diluted EPS | $ per share | [(0.65)](/filings/0001493152-22-009202.md) | [(15.03)](/filings/0001493152-24-011172.md) | [(9.16)](/filings/0001641172-25-000364.md) | [14.90](/filings/0001437749-26-010115.md) | [(5.63)](/filings/0001437749-26-010115.md) | | Free cash flow | $m | [(42.1)](/filings/0001493152-23-007481.md) | [(72.5)](/filings/0001493152-24-011172.md) | [(52.3)](/filings/0001641172-25-000364.md) | [(33.6)](/filings/0001437749-26-010115.md) | [(5.2)](/filings/0001437749-26-010115.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pavm/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Two Seas Capital LP](/funds/1823138.md) | 2026-06-30 | $2.7m | 461,539 | | Unchanged | | [FIRST MANHATTAN CO. LLC.](/funds/728083.md) | 2026-06-30 | $2.0m | 332,911 | | Added +309,106 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $365.9k | 61,604 | | Added +55,687 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $217.9k | 36,678 | | Added +24,901 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $152.1k | 25,605 | | Added +20,176 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $101.5k | 17,092 | | Added +14,676 | | [CWM, LLC](/funds/1535847.md) | 2026-03-31 | $1.6k | 157 | | Not compared | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $968 | 163 | | Reduced −2 | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $446 | 75 | | New +75 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $398 | 67 | | Unchanged | ## Recent filings [All 677 filings](/companies/pavm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 21:28 ET | [8-K](/filings/0001493152-26-048138.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits | 0001493152-26-048138 | | 2026-09-10 | 23:15 ET | [8-K](/filings/0001493152-26-042021.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-042021 | | 2026-08-14 | 14:44 ET | [8-K](/filings/0001493152-26-038072.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-038072 | | 2026-08-13 | 21:03 ET | [10-Q](/filings/0001437749-26-027733.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027733 | | 2026-06-24 | 21:00 ET | [8-K](/filings/0001493152-26-029944.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-029944 | | 2026-05-15 | 12:05 ET | [8-K](/filings/0001493152-26-023352.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-023352 | | 2026-05-14 | 21:17 ET | [10-Q](/filings/0001437749-26-017121.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017121 | | 2026-04-30 | 13:28 ET | [DEF 14A](/filings/0001493152-26-020705.md) | Proxy statement, period 2026-04-30 | 0001493152-26-020705 | | 2026-04-09 | 00:56 ET | [SCHEDULE 13D](/filings/0001094891-26-000179.md) | Ownership report, active investor | 0001094891-26-000179 | | 2026-03-30 | 12:10 ET | [8-K](/filings/0001493152-26-013477.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-013477 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010115.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ca6aa8db-619a-4fae-9a18-fbe3f4edb865) ## About the filer - CIK: 1624326 - Tickers: PAVM - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.